DKMS-BMST
Together, we can delete blood cancer.
Related Articles
Hand therapy interventions for the prevention of chemotherapy-induced peripheral neuropathy of the hands in patients with pancreatic cancer
This trial compared investigational hand therapy intervention with a traditional occupational therapy approach to prevent chemotherapy-induced peripheral n
Toripalimab Plus Chemo Approved in UK for Frontline Nasopharyngeal Carcinoma and ESCC
The UK MHRA approved frontline toripalimab plus chemotherapy for recurrent/metastatic NPC, as well as for advanced, recurrent, or metastatic ESCC.
Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib
Interview with Hagop Kantarjian, MD, author of Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial. Hosted…
PEAR-GLIO Patient & Public Involvement & Engagement Sessions – Pear Bio
Our drug discovery pipeline is focused on a range of indications from breast to lung cancer. Explore more about our pipeline.
Elucidating acquired PARP inhibitor resistance in advanced prostate cancer
Seed et al. explore a cohort of PARPi-treated advanced prostate cancers, studying plasma cell-free DNA samples for genomic alterations that provide drug resistance. They find multiple…
FDA Approves Companion Diagnostic for Tepotinib in mNSCLC Harboring MET Exon 14 Skipping Alterations
The FDA approved the FoundationOne Liquid CDx to identify patients with mNSCLC with MET exon 14 skipping alterations who may be eligible for tepotinib.
Conversations on Cancer – Pediatric Cancers: Navigating the Challenges Together
In conjunction with the European Medicines Agency (EMA), the FDA Oncology Center of Excellence (OCE) will hold a one-hour Conversations on Cancer public pane…
Scientists can predict how long prostate cancer patients will respond
Scientists have worked out a way of predicting how long a prostate cancer patient will continue to respond to the PARP inhibitor drug, olaparib, according…
American Lung Association calls for expanded insurance coverage for lung cancer screening
The American Lung Association is calling on US Congress and state governments to pass insurance reforms that would improve lung cancer screening, treatment, and survival…
Former big tobacco employee no longer part of UK Government cancer advisory committee
A former director for tobacco company Phillip Morris International (PMI), who was serving on a UK Government committee that advises on the carcinogenicity of products,…